Stephens Inc. AR reduced its holdings in shares of Allergan plc (NYSE:AGN) by 7.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 22,560 shares of the company’s stock after selling 1,822 shares during the quarter. Stephens Inc. AR’s holdings in Allergan were worth $3,777,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in AGN. Clearbridge Investments LLC boosted its position in shares of Allergan by 8.6% in the 1st quarter. Clearbridge Investments LLC now owns 9,167,006 shares of the company’s stock valued at $1,342,141,000 after purchasing an additional 726,688 shares during the period. Artisan Partners Limited Partnership boosted its position in shares of Allergan by 6.5% in the 1st quarter. Artisan Partners Limited Partnership now owns 6,767,753 shares of the company’s stock valued at $990,867,000 after purchasing an additional 410,746 shares during the period. FMR LLC boosted its position in shares of Allergan by 42.0% in the 1st quarter. FMR LLC now owns 6,042,005 shares of the company’s stock valued at $884,611,000 after purchasing an additional 1,788,265 shares during the period. Janus Henderson Group PLC boosted its position in shares of Allergan by 27.6% in the 1st quarter. Janus Henderson Group PLC now owns 5,855,576 shares of the company’s stock valued at $857,312,000 after purchasing an additional 1,265,742 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Allergan by 6.6% in the 4th quarter. Geode Capital Management LLC now owns 4,000,839 shares of the company’s stock valued at $533,767,000 after purchasing an additional 247,743 shares during the period. 77.81% of the stock is owned by institutional investors and hedge funds.
AGN has been the subject of several analyst reports. ValuEngine downgraded Allergan from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. SunTrust Banks upped their price objective on Allergan to $185.00 and gave the company a “buy” rating in a research note on Wednesday, July 3rd. UBS Group reduced their price objective on Allergan from $173.00 to $172.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Royal Bank of Canada reaffirmed a “hold” rating and set a $178.00 price objective on shares of Allergan in a research note on Thursday, August 8th. Finally, Barclays upped their price objective on Allergan from $176.00 to $188.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and seven have given a buy rating to the company’s stock. Allergan has a consensus rating of “Hold” and a consensus price target of $179.43.
Allergan (NYSE:AGN) last issued its earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.34 by $0.04. The business had revenue of $4.09 billion during the quarter, compared to the consensus estimate of $3.93 billion. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the prior year, the business posted $4.42 EPS. As a group, analysts predict that Allergan plc will post 16.68 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 13th. Stockholders of record on Tuesday, August 13th will be paid a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.87%. The ex-dividend date of this dividend is Monday, August 12th. Allergan’s dividend payout ratio (DPR) is 17.74%.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Further Reading: How is the Producer Price Index calculated?
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.